Old Web
English
Sign In
Acemap
>
authorDetail
>
Atlas Investigators
Atlas Investigators
Medicine
Bevacizumab
non-small cell lung cancer (NSCLC)
Phase IIIb Trial
Erlotinib
2
Papers
117
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pivotal Trial of the Neuroform Atlas Stent for Treatment of Anterior Circulation Aneurysms: One-Year Outcomes.
2020
Stroke
Osama O. Zaidat
Ricardo A. Hanel
Eric Sauvageau
Amin Aghaebrahim
Eugene Lin
Ashutosh P. Jadhav
Tudor G. Jovin
Ahmad Khaldi
Rishi Gupta
Andrew K. Johnson
Donald Frei
David Loy
Adel M. Malek
Gabor Toth
Adnan H. Siddiqui
John F. Reavey-Cantwell
Ajith J. Thomas
Steven W. Hetts
Brian T. Jankowitz
Atlas Investigators
Show All
Source
Cite
Save
Citations (12)
Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).
2010
Journal of Clinical Oncology
Fairooz F. Kabbinavar
Vincent A. Miller
Bruce E. Johnson
P OConnor
C. Soh
Atlas Investigators
Show All
Source
Cite
Save
Citations (105)
1